Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ribupatide

Phase 3

Ribupatide is one of 51 therapeutic programs targeting Obesity. It is currently in Phase 3.

3

Indications

5

Total Trials

5

Active Trials

50

Competitors

Pipeline

Status by Indication[2][1]

Indication

ObesityRecruiting

Obesity With DiabetesRecruiting

End-Stage Renal DiseaseNot yet recruiting

ObesityPhase 3

Recruiting

Obesity With DiabetesPhase 3

Recruiting

End-Stage Renal DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Cagrilintide

Maridebart Cafraglutide

Retatrutide

Decadron

AAspen Global Incorporated

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Berobenatide

Ribupatide

Survodutide

Boehringer Ingelheim

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Obesity

NCT07458269

Q1 2028

Phase 1Not yet recruiting

End-Stage Renal Disease

NCT07793929

Phase 3Recruiting

Obesity

NCT07284875

Q2 2028

Phase 3Recruiting

Obesity

NCT07284979

Phase 3Recruiting

Obesity With Diabetes

NCT07284901

Clinical

Trials by Indication[1]

Obesity3 trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Recruiting·KKailera·Phase 3·NCT07284875·2,340 enrolled

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Recruiting·KKailera·Phase 3·NCT07284979·1,200 enrolled

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Active, not recruiting·KKailera·Phase 2·NCT07458269·264 enrolled

End-Stage Renal Disease1 trial

A Phase 1, Open Label, Parallel Group Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Ribupatide in Healthy Participants and in Participants Living With Severe Renal Impairment or End Stage Kidney Disease

Not yet recruiting·KKailera·Phase 1·NCT07793929·32 enrolled

Obesity With Diabetes1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Recruiting·KKailera·Phase 3·NCT07284901·1,156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ribupatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ribupatide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kailera company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: KKailera

Related News